NetScientific PLC (LON:NSCI) said its investee company Vortex Biosciences has begun the commercial launch of its VTX1 Liquid Biopsy System. The fully-automated technology offers a breakthrough in early cancer detection in that it is able to collect circulating tumour cells (CTC) from the bloodstream that provide the tell-tale sign of the killer disease. "We believe the technology has several key advantages over current approaches to CTC isolation and has the potential to make a meaningful impact on cancer research and assist the development of innovative diagnostics and therapeutics," said NetScientific chief executive François Martelet. "The commercial launch is a critical milestone for Vortex and brings our portfolio company closer to significant value creation." The AIM-listed investment company owns 95% of Votex having invested just over £13mln in the business. The official launch took place in San Francisco at the Molecular Medicine Tri Conference.
NetScientific hails commercial launch of breakthrough cancer detection device
The official launch took place in San Francisco at the Molecular Medicine Tri Conference.